I think I mentioned that one of the challenges for medical device companies is that 75% of the capital is spent on things like the clinical trials associated with their product, the evidentiary development for reimbursement for health care technology assessment, and so on.
These are not certification exercises. They are not. But currently, the way in which IRAP has been interpreted, it tends to be seen that way.